Delving into the Latest Updates on F4 Pharma GmbH with Synapse

概览

排名前五的药物类型	数量

合成多肽	1

排名前五的靶点	数量

CDH5 x Fibrinogen	1

关联

1

项与 F4 Pharma GmbH 相关的药物

FX-06

靶点

CDH5 x Fibrinogen

作用机制

CDH5调节剂 [+1]

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

100 项与 F4 Pharma GmbH 相关的临床结果

登录后查看更多信息

0 项与 F4 Pharma GmbH 相关的专利（医药）

登录后查看更多信息

1

项与 F4 Pharma GmbH 相关的文献（医药）

2023-05-09·Cells

Microvascular Leakage as Therapeutic Target for Ischemia and Reperfusion Injury.

Review

作者: Kloka, Jan Andreas ; Henning, Rainer ; Friedrichson, Benjamin ; Zacharowski, Kai ; Wülfroth, Petra

Reperfusion injury is a very common complication of various indicated therapies such as the re-opening of vessels in the myocardium or brain as well as reflow in hemodynamic shutdown (cardiac arrest, severe trauma, aortic cross-clamping). The treatment and prevention of reperfusion injury has therefore been a topic of immense interest in terms of mechanistic understanding, the exploration of interventions in animal models and in the clinical setting in major prospective studies. While a wealth of encouraging results has been obtained in the lab, the translation into clinical success has met with mixed outcomes at best. Considering the still very high medical need, progress continues to be urgently needed. Multi-target approaches rationally linking interference with pathophysiological pathways as well as a renewed focus on aspects of microvascular dysfunction, especially on the role of microvascular leakage, are likely to provide new insights.

100 项与 F4 Pharma GmbH 相关的药物交易

登录后查看更多信息

100 项与 F4 Pharma GmbH 相关的转化医学

登录后查看更多信息